Corcept Therapeutics price target raised to $130 from $78 at Canaccord

Canaccord raised the firm’s price target on Corcept Therapeutics (CORT) to $130 from $78 and keeps a Buy rating on the shares. The firm is pounding the table on Corcept Therapeutics because of the strong likelihood of relacorilant approval in Cushing’s 2025, they believe Phase III ROSELLA data will impress in 1Q25, and CATALYST data will continue to drive Cushing’s franchise